ProCE Banner Activity

Community Care Team Workshops: New Frontline Strategies Challenge Longtime Standards in DLBCL

Slideset Download
Download this slideset from a local live webinar to learn how to optimally manage your patients with DLBCL.

Released: March 29, 2022

Expiration: March 28, 2023

Share

Faculty

Jeremy S Abramson

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Program Director Disclosure

Program Director

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc, has disclosed that he has received consultant/advisor/speaker fees from AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb/Celgene, Bluebird Bio, Century, Epizyme, Genentech, Genmab, Incyte, Kite Pharma, Kymera, Lilly, MorphoSys, Mustang Bio, Ono Pharma, and Regeneron.

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he has received consultant/advisor fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, Bayer, Bristol-Myers Squibb, Epizyme, Kymera, Kura, Lilly, MorphoSys, Novartis, Roche/Genentech, Seattle Genetics, BeiGene, TG Therapeutics, and Verastem and fees for non-CME/CE services from BeiGene and Seattle Genetics.